4/A: AVNS CFO Corrects Stock Option Grant Filing

AVANOS MEDICAL's CFO, Scott Galovan, filed an amended Form 4 to correct an error in a previous filing regarding his stock option grant.

Summary

• This filing is an amendment (Form 4/A) to a previous Form 4/A filed on April 1, 2026, by Scott Michael Galovan, SVP, Chief Financial Officer of AVANOS MEDICAL, INC. (AVNS).
• The amendment corrects an erroneous addition to the number of stock options issued to Mr. Galovan on March 13, 2026.
• The original Form 4 filed on March 17, 2026, contained the correct number of stock options, and this amendment aligns with those original figures.
• On March 13, 2026, Mr. Galovan was granted 29,481 time-based restricted share units (TRSUs) pursuant to the Issuer's 2021 Long Term Incentive Plan.
• These TRSUs will vest in three equal installments: 1/3 on March 13, 2027, 1/3 on March 13, 2028, and 1/3 on March 13, 2029.
• He was also granted 69,630 employee stock options on March 13, 2026, with an exercise price of $13.69.
• The stock options will vest 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029, and have an expiration date of March 13, 2036.
• Following these reported transactions, Mr. Galovan beneficially owns 139,824 shares of common stock and 96,212 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices and a minor administrative correction, which does not materially impact the company's operational or financial outlook.

Positives

• SVP, Chief Financial Officer Scott Michael Galovan received significant equity awards, including 29,481 time-based restricted share units and 69,630 employee stock options, aligning his interests with shareholders.
• The company demonstrated transparency and adherence to regulatory requirements by promptly correcting an administrative error in a previous filing.

Negatives

• The company required an amendment (Form 4/A) to correct an error in a prior filing regarding the number of stock options granted, indicating a minor administrative oversight in the initial reporting process.

Risks

• Administrative error in previous filing required correction.

Future Outlook

NA

Management Comments

• NA

Industry Context

StockSavvy.ai notes that equity awards for executives are a standard practice to align management incentives with shareholder value, particularly in the medical device industry where long-term innovation and market penetration are key. The correction of a filing error is a minor administrative issue common in complex regulatory environments.

Comparison to Industry Standards

• Equity compensation packages for senior executives, including a mix of restricted stock units and stock options with multi-year vesting schedules, are standard practice across the healthcare and medical device sectors.
• Companies like Medtronic (MDT) and Stryker (SYK) frequently utilize similar long-term incentive plans to retain talent and incentivize performance.
• The specific grant amounts are commensurate with a Senior Vice President and CFO role in a company of Avanos Medical's size.

Stakeholder Impact

• Shareholders: The interests of the CFO are further aligned with shareholders through equity compensation, potentially fostering long-term value creation.

Next Steps

• Vesting of 1/3 of time-based restricted share units (TRSUs) on March 13, 2027.
• Vesting of 30% of employee stock options on March 13, 2027.
• Vesting of 1/3 of TRSUs on March 13, 2028.
• Vesting of 30% of employee stock options on March 13, 2028.
• Vesting of 1/3 of TRSUs on March 13, 2029.
• Vesting of 40% of employee stock options on March 13, 2029.
• Expiration of employee stock options on March 13, 2036.

Key Dates

Recommendation

This filing primarily concerns an administrative correction to an executive's equity compensation details and a routine grant of long-term incentives. It does not provide new material information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The alignment of executive incentives with shareholder value is a positive, but not a catalyst for a 'buy' recommendation on its own.

Keywords

AVNS, Avanos Medical, Scott Galovan, Form 4/A, SEC filing, stock options, restricted stock units, executive compensation, insider transaction